Switching HIV/AIDS Treatments: Research
- What Are the Consequences of HIV/AIDS Treatment Failure? (October 21, 2009)
A large study of people whose first HIV treatment regimen stopped working and whose subsequent regimen also failed found that one out of four died within the next five years.
In Clinical Infectious Diseases
- Serious Non-AIDS Health Problems (Especially Heart Problems) Appear Less Likely With Truvada Than Epzicom, But Low Bone Mineral Density Is More Likely, Switch Study Finds (October 20, 2009)
In Clinical Infectious Diseases
- Boosted Darunavir Monotherapy Works Well in Two Studies (July 23, 2009)
Ritonavir-boosted darunavir alone maintains HIV suppression in most patients who achieved an undetectable viral load on combination antiretroviral therapy, according to two studies.
From aidsmap.com
- Ritonavir-Boosted Atazanavir as Protease-Only Maintenance Therapy: 48-Week Results (March 12, 2009)
From aidsmap.com
- Switching From Kaletra to Raltegravir Improves Lipid Profiles at the Risk of Viral Rebound (February 10, 2009)
From aidsmap.com
- Second-Line Combinations Fail Twice as Often as First-Line Ones in the First Year (November 16, 2008)
From aidsmap.com
- Switching to AZT From d4T Poses Challenges in Resource-Limited Settings (September 19, 2008)
From aidsmap.com
- Switch to Atazanavir Does Not Reduce Belly Fat (August 4, 2008)
From aidsmap.com
- Clinical Monitoring as Effective as CD4 Count and Viral Load for Deciding When to Switch to Second-Line ART in Poor Countries (April 25, 2008)
From aidsmap.com
- Study Finds More Depression Among People Who Often Switch HIV Medications (July 17, 2007)
From aidsmap.com
- COOL Study: The Ultimate Misnomer? (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Strategic Use of Antiretroviral Therapy: What to Use and When? (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- The Role of Double-Boosted Protease Inhibitors Still Unclear (August 17, 2006)
In XVI International AIDS Conference
- Drugs to Reverse Lipoatrophy Show So-So Effects (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Virologic Suppression Between Six and 18 Months on New Regimen Can Predict Long-Term Outcomes (December 16, 2005)
[Archived Article]
In addition, patients who previously had a treatment interruption appear less likely to succeed on their current regimen.
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- HIV JournalView: Persistent, Low-Level Viremia May Breed Resistance (September 2005)
[Archived Article]
Whether treatment should be switched in viremic patients depends on the regimen and the viral load level, a new study suggests.
From The Body PRO
- Full Virologic Suppression Can Be Maintained With Lopinavir/Ritonavir Alone; Single-Agent Therapies Worth Further Investigation (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Quad Nucleoside/tide Regimen of Trizivir + Tenofovir Effective, Well Tolerated as Second-Line Therapy (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- HIV JournalView: Induction-Maintenance With Zidovudine/Lamivudine/Abacavir (July/August 2005)
[Archived Article]
A much-maligned triple-NRTI combo gets a second look as part of a simplification strategy.
In HIV Treatment ALERTS!, from The Body PRO
- HIV JournalView: Putting Atazanavir + Ritonavir on the Map (July/August 2005)
[Archived Article]
A study finds the combo is comparable to lopinavir/ritonavir in patients with some baseline protease inhibitor resistance.
From The Body PRO
- Dual NRTI Plus Efavirenz Regimen Superior to Boosted PI Plus Efavirenz (February 25, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Strategies for Switching and Simplifying Antiretroviral Treatment in HIV-Infected Patients: Part I: Research Update (February 25, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Strategies for Switching and Simplifying Antiretroviral Treatment in HIV-Infected Patients: Part II: Case Studies (February 25, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Thrush in People on HAART May Be a Sign of Treatment Failure (February 2005)
In this Spanish study, oral candidiasis (also known as thrush) was found in more than 90% of people whose HAART regimens were no longer working.
In AIDS Patient Care and STDs
- Zidovudine/Lamivudine/Abacavir May Be Effective Alone for Induction Maintenance (July 15, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- Confort Study Supports Switch From Protease Inhibitor to Nevirapine (July 14, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- Substituting With Tenofovir Decreases the Adverse Effects Seen With Other NRTIs (July 14, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- Intermittent Drug Switching Can Resensitize Patients With Multidrug-Resistant HIV-1 (July 13, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- NNRTI Not Working? It May Be Safe to Stop It, One Study Suggests (June 28, 2004)
[Archived Article]
If a patient has become resistant to the NNRTI in a HAART combination, cutting the NNRTI out of the regimen appears to do no additional harm.
From aidsmap.com
- Dual-PI Regimen Preferred Over Single-PI Regimen After Initial PI Failure (February 9, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Gastrointestinal Side Effects Lead One in Eight to Change HAART Regimen in First Year of Treatment (November 27, 2003)
[Archived Article]
More than half of new HAART patients were also found to switch or stop their initial regimens within the first year, often without consulting their doctors.
From aidsmap.com
- Dyslipidemia: Change to Tenofovir? (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Switching From PI to Nevirapine in Patients With Undetectable Viral Load Is Safe and Potent (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients With Human Immunodeficiency Virus Infection (September 11, 2003)
[Archived Article]
In The New England Journal of Medicine
- To Switch or Not to Switch: When Is It a Question? (September 2003)
[Archived Article]
Steven Deeks, M.D., offers his wisdom on what options remain for patients who have failed one, two or many HAART regimens.
In The PRN Notebook
- "Mono"-Therapy for HIV Infection Using Ritonavir-Boosted Indinavir (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Atazanavir-Based Once-Daily Regimen Successful in Switch From a Twice-Daily PI-Based Regimen (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Simplification Works! Fewer Pills Mean Better Adherence and Quality of Life (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Substituting AZT or Abacavir for d4T in Patients With Lipoatrophy (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Switch to Nevirapine From Protease Inhibitor Lowers Triglycerides and Maintains Viral Load Suppression (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Assessment of Changes in Adherence and Quality of Life After the Simplification of Antiretroviral Treatment (July 2003)
[Archived Article]
Highlights from the IAPAC Sessions 2003.
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Key Therapeutic Decisions in Managing HIV Infection (Spring 2003)
[Archived Article]
An update on when to start, when to switch and when to stop, from STEP's conference review of Retrovirus 2003.
In STEP Perspective, from Seattle Treatment Education Project
- Improvements in Body Fat and Mitochondrial DNA Levels Are Accompanied by Decreased Adipose Tissue Cell Apoptosis After Replacement of Stavudine Therapy With Either Abacavir or Zidovudine (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Response to a Second Treatment Regimen Following Virologic Failure (February 12, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Efficacy and Safety of AZT/3TC/ABC (Trizivir) Maintenance Treatment After First-Line Quadruple Induction Therapy; Interim 24-Week Data From AZLF3004/TRISUD (November 21, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Pittsburgh: Grant to Fund AIDS Outreach in Black Neighborhoods (November 19, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Successful Switch From Stavudine to Once-Daily Tenofovir Based Regimen in Patients With Fully Suppressed HIV (October 26, 2002)
[Archived Article]
In 40th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Data From the 14th International AIDS Conference: Spare the PIs (October 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Expert Opinion From Barcelona: For Experienced Folks (September/October 2002)
[Archived Article]
In Positively Aware, from Test Positive Aware Network
- Digging Deeper at the Resistance Workshop (August 14, 2002)
[Archived Article]
Key clinical findings from July's XI International HIV Drug Resistance Workshop.
From International AIDS Society
- Expanded Response Analyses of Tenofovir DF Therapy by Baseline Resistance Genotype and Phenotype (July 11, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Is Simplification to Triple Antiretroviral Therapy After Viral Suppression With Quadruple Therapy Initiated at the Time of Primary Infection Associated With Increased Low-Level Viral Breakthrough? (July 11, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Metabolic and Body Composition Changes in Patients Switching From a Protease Inhibitor-Containing Regimen to Abacavir, Efavirenz or Nevirapine; Twelve-Month Results of a Randomized Study (LIPNEFA) (July 11, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Simplification of Protease Inhibitor-Based Highly Active Antiretroviral Regimens With Abacavir Improves Hyperlipidemia and Maintains Viral Suppression in HIV-1-Infected Adults (ESS40003) (July 10, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Switching Protease Inhibitors to Nevirapine, Efavirenz or Abacavir: A Randomized, Multicenter, Open-Label, Simplification Trial (July 10, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Retrospective Analysis of the Use of Tenofovir DF in a Private Practice (July 8, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Quality of Life, Emotional Status, and Adherence of HIV-1-Infected Patients Treated With Efavirenz Versus Protease Inhibitor-Containing Regimens (April 15, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Switching Protease Inhibitors to Nevirapine (NEV), Efavirenz (EFA) or Abacavir (ABA): A Randomized, Multicenter, Open-Label, Simplification Trial (February 28, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- A Randomized Trial of Metabolic and Body Composition Changes in Patients Switching from PI-Containing Regimens to Abacavir (ABC), Efavirenz (EFV) or Nevirapine (NVP) (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Studies Examine Switching Off d4T to Reverse Lipoatrophy (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Long-Term Efficacy and Safety of Emtricitabine (FTC) in HIV-Positive Adults Switching from a Lamivudine (3TC)-Containing HAART Regimen (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Once-Daily Atazanavir Plus Saquinavir Favorably Affects Total Cholesterol (TC) and Fasting Triglyceride (TG) Profiles in Patients Failing Prior PI Therapy (Trial AI424-009, Week 24) (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Safety and Efficacy of Tipranavir (TPV), a Novel Non-Peptidic Protease Inhibitor, Plus Ritonavir (RTV) in PI-Failure Patients (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Virologic Response to Abacavir/Efavirenz/ddI + Hydroxyurea in Subjects Failing Initial NRTI + PI Therapy (NZTA4008 Study) (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Switch to Trizivir Versus Continued HAART Provides Equivalent HIV-1 RNA Suppression at 48 Weeks (TRIZAL - AZL30002) (December 17, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Tenofovir DF: A 24-Week Interim Analysis From a Phase III Double-Blind, Placebo-Controlled Study in Antiretroviral-Experienced Patients (December 17, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Long-Term Follow-Up of MAINTAVIR Study: Substitution of a NNRTI for Protease Inhibitor in Patients on Combination Therapy with Undetectable Plasma Viral Loads (October 29, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Switching From PI-Based to NNRTI-Based Regimens: Clinical and Metabolic Outcomes (October 28, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Clinical Experience of Amprenavir (APV) Following Nelfinavir (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Simplification of Protease Inhibitor-Containing HAART Regimen With Abacavir Maintains Viral Suppression and Favorable Adherence in HIV-1 Infected Adults (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Nelfinavir, Efavirenz, or Both After the Failure of Nucleoside Treatment of HIV Infection (August 9, 2001)
[Archived Article]
In New England Journal of Medicine
- HIV NAT 002.1/002.2: Immediate (IS) Versus Deferred Switching (DS) from ddI/D4T to AZT/3TC in an HIV+ Thai Population and Determine Predictors to Improve Treatment Response to Long-Term Dual Nucleoside Therapy as an Option for Resource-Limited Countries (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Swiss Research Finds That Switching Therapy May Not Lower High Lipid Levels (May 4, 2001)
[Archived Article]
From Canadian AIDS Treatment Information Exchange
- An Open Randomized Study on the Replacement of HIV-1 Protease Inhibitors by Efavirenz in Chronically Suppressed HIV-1-Infected Patients with Lipodystrophy (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Long-Term Efficacy and Tolerance of Switching the Protease Inhibitor for Non-Nucleoside Reverse Transcriptase Inhibitors: A 52-Week, Multicenter, Prospective Study (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Metabolic and Clinical Evaluation of Lipodystrophy Syndrome (LD) in HIV-1-Infected Adults Receiving Initial HAART with or without a Protease Inhibitor (PI): 48-Week Data from the CNAF3007 Study (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- SWATCH Study: A Multicenter Trial of Proactive Treatment Switching. Results at Nine Months of Follow-Up (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Use of Trizivir to Simplify Therapy in HAART-Experienced Patients With Long-Term Suppression of HIV-RNA: TRIZAL Study (AZL30002) -- 24-Week Results (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- "Switch" Studies for People with Lipodystrophy (August 2000)
[Archived Article]
In Project Inform Perspective, from Project Inform
- The Effects of Hydroxyurea or Placebo Combined with Efavirenz, Didanosine, and Stavudine in Treatment of Naive and Experienced Patients: Preliminary 24-Week Results From the Third Study (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- The ADAM Study: Maintenance Therapy After 50 Weeks of Induction Therapy (July 11, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- It Takes Two, Maybe (Spring 2000)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Selected Highlights from the 7th CROI: Combination Drug Studies (Spring 2000)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Selected Highlights from the 7th CROI: Studies of Switching Therapy (Spring 2000)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Snapshots of the Literature (September 1996)
[Archived Article]
In Hopkins HIV Report, from Johns Hopkins AIDS Service
- Another Call for Strategy Trials (August 1996)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
|
|
Advertisement
|
E-Mail
Glossary
Share
